{"id":"pcv-chemotherapy-alone","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"10-20%","effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Methotrexate is an antifolate drug that inhibits dihydrofolate reductase, disrupting DNA synthesis and cell division. Cyclophosphamide is an alkylating agent that cross-links DNA, causing DNA damage and cell death. Vincristine is a vinca alkaloid that binds to tubulin, disrupting microtubule formation and preventing cell division.","oneSentence":"PCV chemotherapy involves the combination of three chemotherapy drugs: methotrexate, cyclophosphamide, and vincristine, which work together to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:53.306Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia"},{"name":"Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT03313778","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2017-08-14","conditions":"Solid Tumors","enrollment":161},{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT04702581","phase":"PHASE3","title":"A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-12-07","conditions":"Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion","enrollment":280},{"nctId":"NCT02444000","phase":"PHASE3","title":"gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-22","conditions":"Anaplastic Gliomas With 1p/19q Codeletion","enrollment":280},{"nctId":"NCT06812221","phase":"PHASE1, PHASE2","title":"Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI","status":"COMPLETED","sponsor":"Biomind Labs Inc.","startDate":"2024-12-15","conditions":"Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder","enrollment":20},{"nctId":"NCT00003375","phase":"PHASE2, PHASE3","title":"Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1998-10","conditions":"Brain and Central Nervous System Tumors","enrollment":370},{"nctId":"NCT02068443","phase":"PHASE3","title":"Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02","conditions":"Type 2 Diabetes Mellitus","enrollment":374},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT03161054","phase":"PHASE2","title":"Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2017-09-12","conditions":"Aggressive Non-Hodgkin Lymphoma","enrollment":21},{"nctId":"NCT04427644","phase":"","title":"Body Mass Index and Obesity Surgery Mortality Risk Score in Perioperative Complications of Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Kahramanmaras Sutcu Imam University","startDate":"2016-01-01","conditions":"Perioperative Complication, Laparascopic Sleeve Gastrectomy, BMD","enrollment":1617},{"nctId":"NCT01678352","phase":"EARLY_PHASE1","title":"Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas","status":"COMPLETED","sponsor":"Frank Lieberman","startDate":"2012-10","conditions":"High Risk WHO Grade II Glioma, Recurrent/Post-Chemotherapy WHO Grade II Glioma","enrollment":19},{"nctId":"NCT03662035","phase":"PHASE2","title":"Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Changzhou No.2 People's Hospital","startDate":"2018-09-15","conditions":"Advanced Pancreatic Cancer","enrollment":30},{"nctId":"NCT00005796","phase":"PHASE1","title":"Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors","status":"COMPLETED","sponsor":"Indiana University","startDate":"2000-02","conditions":"Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ","enrollment":10},{"nctId":"NCT01786018","phase":"PHASE2","title":"Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas","status":"UNKNOWN","sponsor":"Azienda Ospedaliera San Giovanni Battista","startDate":"2013-02","conditions":"B-cell Lymphoma Refractory","enrollment":42},{"nctId":"NCT01339988","phase":"PHASE4","title":"Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2011-06","conditions":"Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndrome","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PCV chemotherapy alone","genericName":"PCV chemotherapy alone","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PCV chemotherapy is used to treat conditions such as solid tumors, oligodendroglioma, low-grade oligodendroglioma, and anaplastic gliomas with 1p/19q codeletion. PCV chemotherapy works by acting as a granulocyte colony-stimulating factor receptor agonist, stimulating the production of white blood cells.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}